Tvardi Therapeutics, Inc. issued a press release on July 7, 2026, providing clinical updates on TTI-109, confirming prodrug design, improved tolerability, and pharmacodynamic evidence of STAT3 target engagement. The company also released an updated corporate presentation. Tvardi Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for cancer treatment.
